Thomas Senderovitz - PAREXEL International Senior Vice President - Clinical Research Services

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

Mr. Thomas Senderovitz, M.D., is Senior Vice President, Clinical Research Services of the Company. since January 2014. In this position he is responsible for the global management of the Companys Early Phase and Clinical Trials and Supplies Logistics business units, as well as the Global Medical Services function. From May 2013 to December 2013 he served as Executive Vice President Global Compound Development at Grunenthal GmbH, a pharmaceutical company. From January 2011 to April 2013, He served as Executive Vice President Global Compound Development Branding at Grunenthal. From February 2010 to January 2011, he served as Senior Vice President Global Clinical Development at Grunenthal. From March 2006 to February 2010 he served as Vice President, Global Exploratory Development at UCB Pharma, a global biopharmaceutical company. Prior to UCB, he held various management positions at FERRING, a global biopharmaceutical company. Dr. Senderovitz received his M.D. from the Faculty of Medicine at the University of Copenhagen.
Age: 48  President Since 2014      
781 487-9900

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Alejandro BernalZoetis
Sripada ChandrasekharDr Reddys Laboratories Ltd
Douglas BoothePerrigo Company plc
Joseph LaRosaRegeneron Pharmaceuticals
Alok SonigDr Reddys Laboratories Ltd
Roxanne LaganoZoetis
Andrew FentonZoetis
Louis YuPerrigo Company plc
Grainne QuinnPerrigo Company plc
Daniel PlewRegeneron Pharmaceuticals
John GrayVertex Pharmaceuticals Incorpor
Peter PowchikRegeneron Pharmaceuticals
Heidi ChenZoetis
Roman TrawickiZoetis
Svend AndersenPerrigo Company plc
Christopher FenimoreRegeneron Pharmaceuticals
Ganadhish KamatDr Reddys Laboratories Ltd
Jeffrey NeedhamPerrigo Company plc
Paul WeningerPerrigo Company plc
James MichaudPerrigo Company plc
Douglas McCorkleRegeneron Pharmaceuticals

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 50 shares of
few hours ago
Traded for 1.0
Purchased over 50 shares of
few hours ago
Traded for 1.0
Purchased over 10K shares of
few hours ago
Traded for 1.0
Purchased over 10K shares of
few hours ago
Traded for 1.0
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.